Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.

Autor:	Yasuoka H; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Kurihara E; Department of Gastroenterology, SUBARU Ota Memorial Hospital, Ota, Japan., Kobatake T; Department of Gastroenterology, SUBARU Ota Memorial Hospital, Ota, Japan., Ijima M; Department of Gastroenterology, SUBARU Ota Memorial Hospital, Ota, Japan., Tamura Y; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Suzuki Y; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Hoshino T; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Ishida F; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Hosaka H; Division of Gastroenterological Medicine, Gunma Prefectural Cancer Center, Ota, Japan., Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan., Yoshida S; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan., Aihara R; Department of Surgery, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan., Hosouchi Y; Department of Surgery, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan., Ishii N; Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan., Araki K; Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan., Shirabe K; Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan., Uraoka T; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan., Kakizaki S; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Jazyk:	angličtina
Zdroj:	Oncology [Oncology] 2022; Vol. 100 (8), pp. 449-459. Date of Electronic Publication: 2022 Jul 11.
DOI:	10.1159/000525742
Abstrakt:	Introduction: This retrospective study investigated the efficacy and safety of nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/L-leucovorin (5-FU/l-LV) treatment in the second-line or later setting for advanced pancreatic cancer under real-world conditions. Methods: Between June 2020 and September 2021, a total of 44 patients with unresectable advanced pancreatic cancer treated with nal-IRI + 5-FU/l-LV in our affiliated hospitals were included. The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated. Results: The median age was 68 (interquartile range 62-73) years old, and 22 patients (50.0%) were male. Concerning tumor factors, 9 patients (20.5%) had local advanced disease and 35 patients (79.5%) had metastases. Twenty-five of the 44 patients were receiving second-line treatment, and 19 were receiving third-line or later treatment. The median overall survival (OS) and progression-free survival were 9.0 (range, 0.7-15.4) months and 4.4 (range, 0.6-15.4) months, respectively. The overall response rate was 5.3%. The disease control rate was 44.7%. Patients with a neutrophil-to-lymphocyte ratio of ≥2.7 had a significant risk of a poor OS (HR = 0.275, p = 0.017). Adverse events were manageable, although gastrointestinal symptoms and neutropenia were observed. The most common grade ≥3 adverse event was neutropenia, which was reported in 20% of patients. Conclusions: Nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice. (© 2022 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu